Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, revenue was PLN 112.84 million compared to PLN 94.76 million a year ago. Net loss was PLN 6.34 million compared to PLN 15.62 million a year ago. Basic loss per share from continuing operations was PLN 0.12 compared to PLN 0.31 a year ago. Diluted loss per share from continuing operations was PLN 0.12 compared to PLN 0.31 a year ago.